RLD2001-1
- Generic Name
- RLD2001-1
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 249
- Registration Number
- NCT06438172
- Locations
- 🇰🇷
Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 166
- Registration Number
- NCT05199129
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 123
- Registration Number
- NCT04820907
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath